NanoMed Pharmaceuticals Founders Issued Broad Patent for Novel Method to Make Nanoparticles
News Jan 05, 2007
NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparticles."
Their invention, assigned to the University of Kentucky Research Foundation and licensed exclusively to NanoMed Pharmaceuticals, covers processes and applications of Nanotemplate Engineering, a nanoparticle manufacturing technology used to formulate small molecules, peptides, proteins, plasmid DNA, and diagnostic agents.
Nanotemplate Engineering involves a rapid, reproducible, and scalable process to manufacture nanoparticles without the need to use expensive equipment commonly required to make other types of pharmaceutical delivery systems.
"We created and developed an engineering process to make nanoparticles that literally takes minutes, and can involve simply mixing all of the ingredients and the drug in a single vessel," said Russell J. Mumper, Ph.D., Associate Professor and Vice Chair of the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Kentucky.
"These nanoparticles can deliver proteins, diagnostic agents and other materials to specific tissues, cells and tumors," Mumper added.
"Drs. Mumper and Jay have shown that these nanoparticles, when manufactured to contain anti-cancer drugs, can deliver the drug more effectively to cancer cells that have developed resistance to the drug when administered alone," said Stephen Benoit, NanoMed President and CEO.
"Based on these data, NanoMed is utilizing Nanotemplate Engineering to develop its lead product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myelogenous leukemia (AML) patients," Benoit added.
Currently, this lead product is in preclinical development and the company expects to begin safety and efficacy tests in AML patients in early 2008, working with Dianna S. Howard, M.D., Associate Professor, Blood and Marrow Transplant Program at the University of Kentucky Lucille P. Markey Cancer Center.
NanoMed intends to expand its Nanotemplate Engineering product pipeline in 2007 to include the development of a second oncology drug targeted to overcome multidrug resistance. In addition, the company is exploring potential partnerships with pharmaceutical companies developing new drugs to overcome resistance in other types of cancer.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE